Andere Sprachen Lisata Therapeutics, Inc.

Aktien

A3DWGC

US1280583022

LSTA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 30.04.2024			% 5 Tage	% 1. Jan.
2,73 ^USD	-0,73 %		+3,02 %	-.--%

23.04.	Lisata Therapeutics, Inc. und Qilu Pharmaceutical Co., Ltd geben bekannt, dass der erste Patient in Qilus Phase-2-Studie in China mit LSTA1 bei Patienten mit metastasiertem duktalem Adenokarzinom der Bauchspeicheldrüse behandelt wurde	CI
17.04.	Lisata Therapeutics, Inc. ernennt James Nisco zum Senior Vice President, Finanzen und Treasury und Chief Accounting Officer	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24.04.
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	23.04.
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	23.04.
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23.04.
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23.04.
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	17.04.
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09.04.
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09.04.
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03.04.
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21.03.
Sector Update: Health Care Stocks Higher in Afternoon Trading	21.03.
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21.03.
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	21.03.
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	04.03.
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29.02.
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	29.02.
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22.02.
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22.02.
Lisata Therapeutics to Present at BIO CEO & Investor Conference	20.02.
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico	18.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Lisata Therapeutics, Inc.

Aktien

A3DWGC

US1280583022

LSTA

Andere Sprachen

Filter